•  

Posts Tagged: PE Hub

ScarX Therapeutics closes $2 million Series A financing

Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)   TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes. This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto. SCX-001 is the ... Read more

Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline

TORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund. This news was covered in PEHub, BetaKit and TechVibes. The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s ... Read more

Xagenic announces $15 million financing round with Series B investors

TORONTO (July 9, 2015) — Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for point-of-care use, today announced that it has raised $15 million (CAD). Each of the company's Series B investors has participated in this financing, including Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation. PE Hub, Cantech Letter, Genome Web, Fierce Medical Devices and the Wall Street Journal's Venture Capital Dispatch blog covered this announcement. In June, Xagenic also announced it has acquired ... Read more

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products. The Wall Street Journal's Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub ... Read more

BlueDot, formerly BioDiaspora Inc., secures Series A with Horizons Ventures

Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A TORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases. Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded ... Read more

Crowdmark to save teacher marking time and government dollars

Ed-tech start-up completes successful EQAO and Canadian Open Math Challenge pilots TORONTO, Canada (June 11, 2013) — Crowdmark Inc., a Canadian education technology start-up, is positioned to save cash-strapped Departments of Education millions by making massive-scale testing more efficient. Crowdmark has raised $600,000 in seed funding through the University of Toronto Early-Stage Technology (UTEST) program, MaRS Innovation and U of T’s Connaught Fund, among others. This story was covered by Yonge Street Media, TechVibes, EdSurge and PEHub. The Crowdmark assessment interface, informed by decades ... Read more